Cargando…
Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer
The liver is the dominant site of metastases for patients with metastatic colorectal cancer (mCRC). Depending on the timing of diagnosis and the biology of the disease, it is not uncommon for these patients to present with visceral crisis in the form of severe liver dysfunction. Treatment of these i...
Autores principales: | Kasi, Pashtoon Murtaza, Thanarajasingam, Gita, Finnes, Heidi D., Villasboas Bisneto, Jose C., Hubbard, Joleen M., Grothey, Axel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4454725/ https://www.ncbi.nlm.nih.gov/pubmed/26090248 http://dx.doi.org/10.1155/2015/420159 |
Ejemplares similares
-
Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck
por: Kasi, Pashtoon Murtaza
Publicado: (2022) -
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study
por: Kasi, Pashtoon M., et al.
Publicado: (2016) -
Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer
por: Shahjehan, Faisal, et al.
Publicado: (2019) -
Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation–associated metastatic renal-cell carcinoma
por: Alsidawi, Samer, et al.
Publicado: (2018) -
Feasibility of Integrating Panel-Based Pharmacogenomics Testing for
Chemotherapy and Supportive Care in Patients With Colorectal Cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2019)